The trajectory of companies tied to flagship drugs like Viagra presents a challenging investment picture. While the initial boom of copyright, fueled by Viagra's extraordinary popularity, generated substantial returns, the patent expiration in key regions has introduced substantial uncertainty . Investors are now facing the impact of rival medicati